23 recruiting, 18 active not recruiting, 8 terminated, 7 completed. 65 Phase 2, 7 Phase 1, 5 Phase 3.
Follow Bone Scan: new trials by email Literature Review of Bone Scan trials Research Report on Bone Scan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer Abiraterone Acetate, Biospecimen Collection, Bone Scan - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 432 | 2027-01-06 | 2026-10-01 |
| Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy Biospecimen Collection, Bone Scan, C. butyricum CBM 588 Probiotic Strain Capsule Formulation MO-03 - Metastatic Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8 | Phase 2 | Not yet recruiting | City of Hope Medical Center | 34 | 2026-11-28 | 2026-05-11 |
| Pluvicto for the Treatment of African American Men With Metastatic Castration-Resistant Prostate Cancer Biopsy Procedure, Biospecimen Collection, Bone Scan - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Not yet recruiting | Emory University | 88 | 2026-11-02 | 2026-10-06 |
| Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial Androgen Receptor Pathway Inhibitor, Transdermal Estrogen, Bone Scan - Castration-Sensitive Prostate Adenocarcinoma, Metastatic Castration-Sensitive Prostate Adenocarcinoma | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 60 | 2026-11-01 | 2026-10-16 |
| Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | Children's Oncology Group | 1708 | 2026-08-28 | 2026-07-30 |
| Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases Zanzalintinib, Investigator Choice of Bone Strengthening Agents (BSA), Non-Investigational Radiation Therapy (RT) - Clear Cell Renal Cell Cancer (ccRCC), Clear Cell Renal Carcinoma | Phase 2 | Recruiting | Kelly Fitzgerald, MD | 20 | 2026-06-10 | 2026-07-27 |
| Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer Biopsy, Biospecimen Collection, Bone Scan - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | University of Michigan Rogel Cancer Center | 20 | 2026-06-01 | 2026-05-05 |
| High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer Radiation Therapy, Pembrolizumab, Nab-paclitaxel - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma | Phase 2 | Recruiting | Emory University | 29 | 2025-10-22 | 2026-04-17 |
| Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer Biospecimen Collection, Bone Scan, Capecitabine - Anatomic Stage IV Breast Cancer AJCC v8, Estrogen-receptor-positive Breast Cancer | Phase 2 | Recruiting | Mayo Clinic | 35 | 2025-10-01 | 2026-08-12 |
| A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations Pemigatinib, Computed Tomography (CT), Magnetic Resonance Imaging - Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma | Phase 2 | Recruiting | Sameek Roychowdhury | 40 | 2025-08-26 | 2026-02-17 |
| A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer Abemaciclib, Biopsy, Bone Scan - Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm | Phase 2 | Terminated | OHSU Knight Cancer Institute | 6 | 2025-06-24 | 2026-04-28 |
| Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease Biospecimen Collection, Bone Scan, Computed Tomography - Metastatic Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Recruiting | University of Washington | 51 | 2025-04-29 | 2026-07-07 |
| Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer Gonadotropin Releasing Hormone Agonists and Antagonists, Bicalutamide, Biopsy Procedure - High Risk Prostate Carcinoma, Localized Prostate Adenocarcinoma | Phase 2 | Withdrawn | OHSU Knight Cancer Institute | 2025-04-16 | 2025-09-23 | |
| Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan - Recurrent Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 37 | 2025-03-18 | 2026-06-25 |
| Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial Genetic testing, Valemetostat Tosylate, Magnetic Resonance Imaging - Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Recruiting | Alliance for Clinical Trials in Oncology | 474 | 2025-02-06 | 2026-10-02 |
| Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer Anti-STEAP1 CAR T-cells, Biopsy Procedure, Biospecimen Collection - Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 48 | 2024-11-26 | 2026-08-11 |
| Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer Biopsy Procedure, Biospecimen Collection, Bone Scan - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 15 | 2024-09-18 | 2026-08-06 |
| Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial) Binimetinib, Biopsy Procedure, Biospecimen Collection - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 1 | 2024-09-13 | 2026-03-03 |
| An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer Biospecimen Collection, Bone Scan, Computed Tomography - Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma | Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 91 | 2024-08-06 | 2026-06-15 |
| Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer Biospecimen Collection, Bone Scan, Computed Tomography - Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma | Phase 2 | Recruiting | City of Hope Medical Center | 18 | 2024-07-23 | 2026-10-07 |
Showing 20 of 65. Sign in to see all of them.
Prostatic Neoplasms (28) · Carcinoma, Renal Cell (9) · Wilms Tumor (5) · Central Nervous System Neoplasms (4) · Ependymoma (4) · Glioma (4) · Hepatoblastoma (4) · Histiocytosis, Langerhans-Cell (4) · Lymphoma, Non-Hodgkin (4) · Medulloblastoma (4) · Neuroblastoma (4) · Neuroectodermal Tumors, Primitive, Peripheral (4) · Osteosarcoma (4) · Rhabdoid Tumor (4) · Breast Neoplasms (3)
National Cancer Institute (NCI) (26) · Mayo Clinic (5) · University of Washington (4) · Fred Hutchinson Cancer Center (3) · NRG Oncology (3) · OHSU Knight Cancer Institute (3) · Children's Oncology Group (2) · City of Hope Medical Center (2) · Emory University (2) · The European Uro-Oncology Group (2) · Alliance for Clinical Trials in Oncology (1) · ECOG-ACRIN Cancer Research Group (1) · Jonsson Comprehensive Cancer Center (1) · Kelly Fitzgerald, MD (1) · Massachusetts General Hospital (1)
United States (59) · Puerto Rico (11) · Canada (10) · Australia (7) · Hong Kong (2) · Netherlands (2) · New Zealand (2) · Singapore (2) · China (1) · Ireland (1) · Saudi Arabia (1) · Taiwan (1)
Michael Schweizer (3) · Andrea B Apolo (2) · Sumanta K Pal (2) · Susanne Osanto, MD PhD (2) · Alexander N Shoushtari (1) · Alice Lee (1) · Andrei Iagaru, MD (1) · Angela Castellanos Rodriguez, MD, MSc (1) · Anish Thomas, M.D. (1) · Ardaman Shergill (1) · Arthur Hung (1) · Benjamin L Maughan (1) · Bora Lim (1) · Brian Shuch (1) · Bridget F Koontz (1)
PMID 23455520, PMID 26405167, PMID 26956325, PMID 30227893, PMID 31236756, PMID 31401903, PMID 32897402, PMID 33591402, PMID 33592176, PMID 33602696, PMID 33604999, PMID 34486544, PMID 35031545, PMID 35353553, PMID 37146227, PMID 39255440, PMID 39938471, PMID 41166674, PMID 41785440, PMID 42117295, PMID 42498485, PMID 42507969, PMID 42686334, PMID 42820295
U10CA180821 (8), U10CA180886 (7), U10CA180868 (5), P30CA033572 (2), P30CA138292 (2), P50CA097186 (2), U10CA180820 (2), U10CA180888 (2), UM1CA186644 (2), UM1CA186689 (2), P30CA060553 (1), P30CA168524 (1), R01CA286127 (1), R01CA300454 (1), R37CA286450 (1)